- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Earnings Call Transkript: FluoGuide treibt US-Krebsstudie im ersten Halbjahr 2026 voran | 1 | Investing.com Deutsch | ||
| 25.08. | FluoGuide A/S Q2 Loss Increases | 2 | RTTNews | ||
| 25.08. | FluoGuide A/S Publishes Interim Report for Q2 2026 | 289 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 25, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 30 June 2026. The Q2 report is... ► Artikel lesen | |
| 12.08. | Invitation to FluoGuide A/S Live Webcast on 25 August 2026 | 315 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / August 12, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026.Later that day, CEO Morten Albrechtsen and CFO Ole... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 01.07. | FluoGuide A/S: Update on 2026 Outlook and Company Progress | 418 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an... ► Artikel lesen | |
| 29.06. | FluoGuide A/S: FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial | 397 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.05. | FluoGuide A/S Publishes Interim Report for Q1 2026 | 434 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available... ► Artikel lesen | |
| 13.05. | Invitation to FluoGuide A/S Live Webcast on 27 May 2026 | 350 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 10.04. | FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG | 221 | GlobeNewswire (Europe) | Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer.
The interim data from... ► Artikel lesen | |
| 25.03. | Minutes from Annual General Meeting in FluoGuide A/S | 495 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 18.03. | FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma | 393 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces... ► Artikel lesen | |
| 10.03. | Notice of Annual General Meeting in FluoGuide A/S | 502 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025 | 629 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Interim Report For Q4 2025 | 396 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report... ► Artikel lesen | |
| 20.02. | FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track | 743 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer... ► Artikel lesen | |
| 19.02. | Invitation to FluoGuide A/S Live Webcast on 25 February 2026 | 309 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 21.01. | FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial | 365 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 482 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11.25 | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 511 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11.25 | Minutes from Extraordinary General Meeting in FluoGuide A/S | 414 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 45,100 | -0,42 % | Fresenius-Aktie: Score 4 - Der Patient in der Genesung - Warren Wise Podcast | Genesung ist noch keine Kerngesundheit. Fresenius meldet das beste Jahr seit Langem. Der Gewinn hat sich mehr als verdoppelt, die Schulden sind gesunken, und die Dividende ist zurück. Der Vorstand erklärt... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,970 | -1,69 % | EQS-News: CPT GmbH: Warren Wise scannt Siemens Healthineers: Scharfe Bilder für Ärzte, unscharfe für Investoren | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise scannt Siemens Healthineers: Scharfe Bilder für Ärzte, unscharfe für Investoren
18.09.2026... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 38,850 | -0,79 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 55,85 | -1,61 % | Here's What Lifted BrightSpring Health Services (BTSG) | ||
| ALIGNMENT HEALTHCARE | 8,310 | -0,48 % | Alignment Healthcare extends retreat, falls an additional 16% | ||
| HEARTFLOW | 50,37 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,430 | -1,65 % | Aveanna Healthcare auf dem Deutsche Bank Healthcare Summit 2026: Neuausrichtung auf Wachstumskurs | ||
| LIFESTANCE HEALTH GROUP | 12,685 | +0,87 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| GENEDX | 97,78 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| PROGYNY | 26,865 | 0,00 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| BILLIONTOONE | 103,78 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 29,080 | +1,52 % | Aktien KW 38 Warsh konnte nicht bremsen. Iran verhindert mehr. TACO gefragt! News. Rheinmetall. Mutares. Verbio. Lufthansa. Hapag Lloyd. Carl Zeiss MediTec. Verbio. BASF. DEFAMA. Vonovia. Aroundtown. SFC Energy. Dürr. Evonik. Continental. Elmos Semiconduc | Aktien - es gab eine Leitzinserhöhung in den USA. Da von allen erwartet konnten die Aktienmärkte damit relativ gut umgehen. Selbst Gold und Silber atmeten einmal kurz ein udn setzten danach zum neuen... ► Artikel lesen | |
| BETA BIONICS | 22,020 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 19,540 | -1,51 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| GERRESHEIMER | 26,240 | -1,82 % | EQS-PVR: Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Gerresheimer AG
Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.09.2026 / 08:53 CET/CEST
Veröffentlichung... ► Artikel lesen |
Das Unternehmen FLUOGUIDE A/S kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-3,47 %) liegt der Kurs bei 2,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.